- €2.55bn
- €12.31bn
- $4.96bn
- 48
- 91
- 85
- 89
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 3,391 | 3,496 | 3,672 | 4,913 | 4,963 |
Cost of Revenue | |||||
Gross Profit | 934 | 889 | 846 | 1,182 | 1,420 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 2,649 | 2,891 | 2,938 | 3,893 | 3,818 |
Operating Profit | 742 | 605 | 734 | 1,020 | 1,145 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 542 | 366 | 543 | 660 | 589 |
Provision for Income Taxes | |||||
Net Income After Taxes | 511 | 328 | 472 | 556 | 614 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 366 | 191 | 400 | 451 | 491 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 366 | 191 | 400 | 450 | 491 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 1.93 | 1.74 | 1.74 | 2.92 | 2.84 |
Dividends per Share |